| First Author | Liu M | Year | 2020 |
| Journal | Nature | Volume | 587 |
| Issue | 7832 | Pages | 115-120 |
| PubMed ID | 33087928 | Mgi Jnum | J:297412 |
| Mgi Id | MGI:6472596 | Doi | 10.1038/s41586-020-2836-1 |
| Citation | Liu M, et al. (2020) TGF-beta suppresses type 2 immunity to cancer. Nature 587(7832):115-120 |
| abstractText | The immune system uses two distinct defence strategies against infections: microbe-directed pathogen destruction characterized by type 1 immunity(1), and host-directed pathogen containment exemplified by type 2 immunity in induction of tissue repair(2). Similar to infectious diseases, cancer progresses with self-propagating cancer cells inflicting host-tissue damage. The immunological mechanisms of cancer cell destruction are well defined(3-5), but whether immune-mediated cancer cell containment can be induced remains poorly understood. Here we show that depletion of transforming growth factor-beta receptor 2 (TGFBR2) in CD4(+) T cells, but not CD8(+) T cells, halts cancer progression as a result of tissue healing and remodelling of the blood vasculature, causing cancer cell hypoxia and death in distant avascular regions. Notably, the host-directed protective response is dependent on the T helper 2 cytokine interleukin-4 (IL-4), but not the T helper 1 cytokine interferon-gamma (IFN-gamma). Thus, type 2 immunity can be mobilized as an effective tissue-level defence mechanism against cancer. |
